Mark S. Forman - 04 Mar 2026 Form 4 Insider Report for Ventyx Biosciences, Inc. (VTYX)

Reporting relationship: Chief Medical Officer
Issuer ticker: VTYX
Reported as of: 04 Mar 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 04 Mar 2026, 16:15:13 UTC
Prior SEC filing: 19 Nov 2025
Source filing: View source filing
Reporting owner signature: /s/ Austin Rutherford, as Attorney-in-Fact

Key filing fact

Mark S. Forman filed Form 4 for Ventyx Biosciences, Inc. (VTYX) on 04 Mar 2026.

Key facts

This page summarizes Mark S. Forman's Form 4 filing for Ventyx Biosciences, Inc. (VTYX).
3 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 04 Mar 2026, 16:15.

Change

Previous filing in this sequence was filed on 19 Nov 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001922353 Primary reporting owner

Forman Mark S

Relationship: Chief Medical Officer
Address: 12790 EL CAMINO REAL, SUITE 200, SAN DIEGO
Signature: /s/ Austin Rutherford, as Attorney-in-Fact
Signature date: 04 Mar 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

VTYX transaction

Common Stock

Disposed to Issuer

Transaction value
Shares: -6,000
Change %: -100%
Price
Shares after: 0
Date: 04 Mar 2026
Ownership: Direct
Footnotes: F1, F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

VTYX transaction Derivative

Stock Option (Right to Buy)

Disposed to Issuer

Transaction value
Shares: -85,000
Change %: -100%
Price
Shares after: 0
Date: 04 Mar 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 85,000
Exercise price: $2.14
Footnotes: F1, F3

VTYX transaction Derivative

Stock Option (Right to Buy)

Disposed to Issuer

Transaction value
Shares: -350,000
Change %: -100%
Price
Shares after: 0
Date: 04 Mar 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 350,000
Exercise price: $1.95
Footnotes: F1, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Section 16 status

Mark S. Forman is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.

Explanation of responses 3 footnotes

Footnote F1

Pursuant to the Agreement and Plan of Merger, dated January 7, 2026 (as it may be amended from time to time, the "Merger Agreement"), by and among Ventyx Biosciences, Inc. ("Issuer") , Eli Lilly and Company ("Parent"), and Parent's wholly owned subsidiary, RYLS Merger Corporation ( "Merger Sub"), the Merger Sub merged with and into the Issuer (the "Merger"), with the Issuer surviving the Merger and becoming a wholly owned subsidiary of the Parent.

Footnote F2

At the effective time of the Merger (the "Effective Time"), these shares were automatically converted solely into the right to receive cash in an amount equal to $14.00 (without interest) per share (the "Per Share Price"), subject to the terms and conditions of the Merger Agreement.

Footnote F3

At the Effective Time, this option to purchase shares of the Issuer's common stock had an exercise price per share that was less than or equal the Per Share Price and, pursuant to the terms of the Merger Agreement, at the Effective Time, was automatically cancelled and converted into the right to receive an amount in cash equal to (i) the total number of shares of common stock subject to the option, multiplied by (ii) the excess, if any, of the Per Share Price over the exercise price per share of such option, without interest and less any applicable withholding taxes.